• Nosocomial pneumonia (NP) has been reported to be the second most frequent hospital-acquired infection in the United States [1] .
• Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for a large number of cases of health careassociated pneumonia, hospital-acquired pneumonia, and ventilator-associated pneumonia [2, 3] .
• Appropriate and timely empiric treatment is important for MRSA-related infections. Inadequate empiric treatment is associated with increased mortality and longer hospital stay. [4, 5] 
BACKGROUND
• Key results from base-case model are summarized in Table 3 .
• Overall, treatment with Emp-LIN was associated with lower total costs (by a mean of $313), and marginally greater QALY gain and overall treatment success compared to Emp-VAN, resulting in Emp-LIN 'dominating' Emp-VAN.
• Compared to NE-MRSA, Emp-LIN was more costly by $1,626, but had greater QALY gain (+0.836) and incremental treatment success (+5.9%), resulting in an incremental cost effectiveness ratio (ICER) of $1,946 per QALY gain, and $27,750 per successfully treated patient.
• One-way sensitivity analysis ( Figure 2 ) indicated days in ICU stay, clinical efficacy, and MRSA rate had the greatest impact on ICER based on CEA.
• Based on PSA findings, probability of Emp-LIN being cost-effective was 61% (vs. Emp-VAN) and 99% (vs. NE-MRSA) assuming a willingness-to-pay (WTP) of $50,000 per successfully treated patients and QALY gain respectively
RESULTS
• The purpose of this analysis was to compare the economic impact of initial empiric linezolid (Emp-LIN) vs. vancomycin (Emp-VAN) vs. no empiric MRSA coverage (NE-MRSA) before culture-confirmed treatment, for suspected MRSA NP. After MRSA confirmation, the model allows patients to continue on first/second line linezolid or vancomycin treatment.
• Rationale:
-To our knowledge, no previous studies have focused on cost effectiveness of empiric treatment options for suspected MRSA NP.
OBJECTIVE
• In conclusion, this US health economic model showed that in a hospital setting with 30% MRSA rate, early treatment with Emp-LIN can be a cost-effective alternative compared to Emp-VAN and NE-MRSA at reasonable WTP threshold.
• Hence, initiating empiric treatment with linezolid should be considered a preferred treatment choice, especially at hospitals with high MRSA rate.
• Cost-effectiveness of linezolid was primarily driven by its higher clinical response rate.
• Future analyses should use other country costs/resource use data to test result generalizability
CONCLUSION
• Funding for this study was provided by Pfizer Inc.
DISCLOSURE
• A total payer perspective was considered in the base case analysis, which was comprehensive and comprised all inpatient and outpatient health care costs (antibiotic and medical).
• Patients entered the model when diagnosed with an episode of suspected gram+ NP, and could receive treatment with empiric linezolid, vancomycin, or no empiric MRSA coverage (Figure 1a ).
• Patients with negative culture for MRSA (i.e., methicillinsensitive Staphylococcus aureus [MSSA]) got assigned aggregated costs and outcomes for MSSA treatment.
Patients with positive culture entered the confirmed MRSA treatment phase (Figure 1b) . The proportion of patients with MRSA confirmation can vary in the model (base-case value was 30%).
• Possible treatment outcomes associated with therapy after MRSA confirmation were: 1) treatment success; 2) failure due to lack of efficacy among survivors; 3) drug discontinuation due to AEs; or 4) failure due to death
METHODS
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• The model was primarily based on clinical and resource use data from a recently published clinical trial comparing linezolid and vancomyin in MRSA NP [6] (Table 1 ).
• After any failure of first-line treatment or discontinuation due to AEs, patients were switched to second-line treatment (e.g., patients who failed first-line treatment with linezolid switched to vancomycin and vice versa). In the base-case scenario, the switch was assumed to be after 7 days of first-line treatment, with second-line treatment duration of 10 days. The model did not include a third-line treatment.
• The model made several assumptions, and a few key ones are listed below:
-Patients with MSSA were assumed to have efficacy proportions, LY and QALY similar to the MRSA cohort. Hence, the model used the mean of linezolid and vancomycin values for the MSSA cohort. This assumption does not affect the model results/ conclusions across treatment arms, since it is applied uniformly to all treatment arms, and does not introduce any bias.
-In the absence of published data for second-line treatment, the clinical inputs for second-line treatment were the same as for first-line treatment [7] .
• Health utility data for the model was obtained from published literature.
Sensitivity Analysis:
• A univariate (one-way) sensitivity analyses was conducted to assess the impact of model uncertainties and robustness of our analysis. Key model parameters were individually varied within the pre-defined sensitivity ranges, and ICERs were recorded. A published source was used for ranges whenever possible. In absence of strong published data, an arbitrary range was used (such as +/-4 days for length of stay, or +/-25% for costs).
• A probabilistic sensitivity analysis (PSA) was also performed, wherein all parameters were varied simultaneously within their range using 10,000 second order Monte Carlo simulations. Gamma distribution was specified for resource use and cost variables, and beta distribution for probability variables.
-Because the model used the 60-day mortality rates reported in the clinical trial [6] that represented total mortality and included deaths from first-line and second-line treatment, mortality occurred only at the end of first-line treatment to avoid overestimation attributable to double-counting. Because the first-line mortality rates between linezolid and vancomycin did not differ in the clinical trial, these rates were considered the same in this model.
